Summary
Early administration of eplerenone added to standard treatment in postmyocardial infarction patients appears to reduce the risk of adverse cardiovascular outcomes and heart failure, according to results from the Impact of Eplerenone on Cardiovascular Outcomes in Patients Post-Myocardial Infarction trial [REMINDER; NCT01176968].
- Heart Failure
- Cardiology Clinical Trials
- Myocardial Infarction
- Heart Failure
- Cardiology Clinical Trials
- Myocardial Infarction
- Cardiology
- © 2013 MD Conference Express®
Tools
Eplerenone Post Myocardial Infarction Plus Standard Treatment May Prevent Adverse Cardiovascular Outcomes
Permalink:
Table of contents
Cited By...
- No citing articles found.